Arthritis Research UK National Primary Care Centre, Primary Care Sciences, Keele University, Keele, Staffordshire ST5 5BG, UK.
Rheumatology (Oxford). 2010 Dec;49(12):2346-56. doi: 10.1093/rheumatology/keq245. Epub 2010 Aug 16.
To assess overall responses to treatments among non-specific low back pain (NSLBP) patients in clinical trials to examine the pattern following a wide range of treatments.
We conducted a systematic review of published trials on NSLBP and meta-analysis of within-group responses to treatments calculated as the standardized mean difference (SMD). We included randomized controlled trials that investigated the effectiveness of primary care treatments in NSLBP patients aged≥18 years. Outcome measures included the visual analogue scale for pain severity, Roland Morris Disability Questionnaire and Oswestry Disability Index for physical functioning.
One hundred and eighteen trials investigating a wide range of primary care treatment for NSLBP were included. Plots of response to treatments showed that there was a similar pattern of initial improvement at 6 weeks followed by smaller improvement for both pain and functional disability at long-term follow-up. This was also shown by the pooled SMD for pain which was 0.86 (95% CI 0.65, 1.07) at 6 weeks, 1.07 (95% CI 0.87, 1.27) at 13 weeks, 1.03 (95% CI 0.82, 1.25) at 27 weeks and 0.88 (95% CI 0.60, 1.1) at 52 weeks. There was a wide heterogeneity in the size of improvement. This heterogeneity, however, was not explained by differences in the type of treatment classified as active, placebo, usual care or waiting list controls or as pharmacological or non-pharmacological treatment.
NSLBP symptoms seem to improve in a similar pattern in clinical trials following a wide variety of active as well as inactive treatments. It is important to explore factors other than the treatment, that might influence symptom improvement.
评估临床试验中针对非特异性下腰痛(NSLBP)患者的整体治疗反应,以检查广泛治疗后的模式。
我们对 NSLBP 的已发表试验进行了系统评价,并对组内治疗反应进行了荟萃分析,计算为标准化均数差(SMD)。我们纳入了调查≥18 岁 NSLBP 患者初级保健治疗有效性的随机对照试验。结局指标包括疼痛严重程度的视觉模拟评分、Roland Morris 残疾问卷和 Oswestry 残疾指数的身体功能。
纳入了 118 项针对 NSLBP 的广泛初级保健治疗的试验。治疗反应的图表明,在 6 周时出现了类似的初始改善模式,随后在长期随访时疼痛和功能障碍的改善较小。6 周时疼痛的汇总 SMD 为 0.86(95%CI 0.65,1.07),13 周时为 1.07(95%CI 0.87,1.27),27 周时为 1.03(95%CI 0.82,1.25),52 周时为 0.88(95%CI 0.60,1.1),改善的幅度存在很大的异质性。然而,这种异质性不能用分类为活性、安慰剂、常规护理或等候名单对照的治疗类型,或药理学或非药理学治疗的差异来解释。
在临床试验中,NSLBP 症状似乎以类似的模式改善,无论是接受广泛的活性治疗还是非活性治疗。重要的是要探讨除治疗以外可能影响症状改善的因素。